Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2
Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51 | Sarepta Therapeutics, Inc. Investor Relations | Sarepta…